Gemcitabine

Catalog No.S1714 Synonyms: LY-188011, NSC 613327

Gemcitabine  Chemical Structure

Molecular Weight(MW): 263.2

Gemcitabine, a nucleic acid synthesis inhibitor, is a very potent and specific deoxycytidine analogue, used as chemotherapy.

Size Price Stock Quantity  
In DMSO USD 130 In stock
USD 97 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • Mice were administered either vehicle, gemcitabine (120 mg/kg [PaCa2]) or 20 mg/kg of BBI608 i.p. After killing, tumors were collected after 7 or 14 d of treatment, for Paca-2 and FaDu cells, respectively. Single-cell suspensions were obtained after animal killing and sterile removal of tumors. Live cells were then counted and used to measure their ability to form spheres when cultured in cancer stem cell media.

    Proc Natl Acad Sci USA, 2015, 112(6): 1839-44. Gemcitabine purchased from Selleck.

    RNA incorporating drugs induce SG assembly. HeLa cells were treated with the RNA incorporating agents 5-azacytidine (50 uM) and 6-thioguanine (10 uM), or the DNA incorporating agents trifluorothymidine (10 uM) and gemcitabine (100 nM) for 72 h. Subsequently, the cellular localization of the SG marker protein TIAR (green) and the P-body marker protein DCP1 (red) was analyzed. Nuclei were stained with Hoechst. Scale bars represent 20 um.

    Nucleic Acids Res 2014 42(10), 6436-47. Gemcitabine purchased from Selleck.

  • Immunofluorescent analysis of gemcitabine-induced γH2A.X and 53-BP1 focus formation. a, b Immunofluorescence staining of γH2A.X(green), 53-BP1 (red), and nuclei staining with DAPI (blue) in T24 (a) and T24r GEMCI20 (b) cells after the indicated treatments. Scale bar = 50 μm

    J Exp Clin Cancer Res, 2017, 36(1):1. Gemcitabine purchased from Selleck.

    Cells were seeded in 96 well paltes, and then treated with the indicated concentration of Gemcitabine for 48h. Cell survival was measured by a standarad MTT assay.

    Dr. Helen Sadik of Johns Hopkins University. Gemcitabine purchased from Selleck.

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Gemcitabine, a nucleic acid synthesis inhibitor, is a very potent and specific deoxycytidine analogue, used as chemotherapy.
In vitro

Gemcitabine results in 50% inhibition of growth in the CCRF-CEM human leukemia cell culture assay with IC50 of 1 ng/ml. Gemcitabine combined with deoxycytidine provides about a 1000-fold decrease in biological activity. [1] Gemcitabine combined with C225 results in additive cytotoxic effects that increased with increasing gemcitabine concentrations in human pancreatic carcinoma L3.6pl cells. [2] Gemcitabine combined with Cisplatin results in synergistic effect in wild-type A2780 and cisplatin-resistant ADDP cells. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV-4-11 NEXE[2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{[wcWlEPTB;MD6wNFA1PThibl2= MVvTRW5ITVJ?
ES4 MkXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjFcI1KSzVyPUCuNFAxPjV|IH7N M{n2cnNCVkeHUh?=
ACHN MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjiXnBKSzVyPUCuNFAxQDh5IH7N NF;UNZJUSU6JRWK=
KYSE-510 NG\RXYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTBwMECwPVc2KG6P MVPTRW5ITVJ?
EW-7 M1nMNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzQTWM2OD1yLkCwNlU5KG6P MnTZV2FPT0WU
BFTC-905 M17KV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInsW41KSzVyPUCuNFA2OTVibl2= M2r4fHNCVkeHUh?=
KE-37 NVLwbXJsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTBwMEC1OlEhdk1? NWCydHkxW0GQR1XS
SBC-5 NV[5SJVpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHuTWM2OD1yLkCwOVchdk1? M1\FZnNCVkeHUh?=
NKM-1 NUjzVJRwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjETWM2OD1yLkCwO|A6KG6P NEDJZotUSU6JRWK=
RH-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTBwMEC3NVghdk1? NGP4b45USU6JRWK=
ALL-PO Mlu3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUH1[3FrUUN3ME2wMlAxQDNibl2= NXzTdnlkW0GQR1XS
QIMR-WIL MmOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYWxUpM{UUN3ME2wMlAxQDl2IH7N MkPtV2FPT0WU
A375 MnjaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjPVXNSUUN3ME2wMlAxQTl3IH7N NVH6RmhvW0GQR1XS
SIG-M5 MoX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlv2TWM2OD1yLkCxNFQhdk1? M4PDUHNCVkeHUh?=
KGN NYn5Vo5IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTWTWM2OD1yLkCxNFghdk1? Mki0V2FPT0WU
EW-13 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTBwMEGxNkBvVQ>? MWXTRW5ITVJ?
NCI-SNU-1 NV71eFdwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTBwMEG2JI5O NW\6WpRxW0GQR1XS
PSN1 M3TRfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTBwMEG2OUBvVQ>? MUTTRW5ITVJ?
HUTU-80 NW\6UVJJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\PR2lEPTB;MD6wNVY3KG6P MljQV2FPT0WU
EW-16 MoLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTBwMEKzJI5O M16wdHNCVkeHUh?=
786-0 NWDLU3l6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHRNW9pUUN3ME2wMlAzOyCwTR?= NWD6bW8yW0GQR1XS
ES1 NELE[FdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzXSXZKSzVyPUCuNFI3QCCwTR?= M1jqWXNCVkeHUh?=
RKO MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVS1fVdoUUN3ME2wMlAzPzlibl2= M{HJc3NCVkeHUh?=
ESS-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH6xPFJKSzVyPUCuNFI5PiCwTR?= Ml:5V2FPT0WU
SK-UT-1 M4TBd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVT6XFBxUUN3ME2wMlAzQTdibl2= M16wcXNCVkeHUh?=
LB2241-RCC NXTaTVJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2Tic2lEPTB;MD6wN|E5KG6P M1jnR3NCVkeHUh?=
CHL-1 MmixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfCOGRKSzVyPUCuNFMzPCCwTR?= MoPhV2FPT0WU
SW1783 NGHpdWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTBwMEOzOkBvVQ>? NG\MfHNUSU6JRWK=
MEL-JUSO NUW0PXBjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTBwMEO5NUBvVQ>? MUXTRW5ITVJ?
HT-29 MmrSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmflTWM2OD1yLkC0NVMhdk1? MmHkV2FPT0WU
SNG-M NHjiNIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTBwMESyOUBvVQ>? MnLTV2FPT0WU
TE-15 M4nSfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HKfGlEPTB;MD6wOFY1KG6P MYPTRW5ITVJ?
HOS MmruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTBwMES4JI5O NEL2TlNUSU6JRWK=
BB65-RCC Mn\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3Ic2txUUN3ME2wMlA2OTJibl2= MVLTRW5ITVJ?
HCE-4 M136WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\JdHZoUUN3ME2wMlA2Ojhibl2= NXf1cIwyW0GQR1XS
MHH-ES-1 NFHi[IhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzOTWM2OD1yLkC1N|Ehdk1? MWDTRW5ITVJ?
RPMI-7951 NYTXSVdjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTBwMEW0NUBvVQ>? NIn3WWhUSU6JRWK=
IST-SL2 MkXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTBwMEW4OEBvVQ>? NXqxdpd5W0GQR1XS
CMK NGTSXFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTBwMEW4OkBvVQ>? MVrTRW5ITVJ?
GR-ST MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXe3[|ZMUUN3ME2wMlA2QTVibl2= NUnmd4x2W0GQR1XS
NALM-6 NYe3S45QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDyeXhKSzVyPUCuNFYzOiCwTR?= NXXYdJU2W0GQR1XS
RPMI-6666 NV75[XpsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPIOmVKSzVyPUCuNFY2OiCwTR?= MYrTRW5ITVJ?
LC-2-ad MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGK4SZdKSzVyPUCuNFY2OyCwTR?= MknWV2FPT0WU
ARH-77 NUfZNllIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoX3TWM2OD1yLkC3NVEhdk1? MXvTRW5ITVJ?
IST-MEL1 M{TCVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHMdmdwUUN3ME2wMlA4OjZibl2= M13UOHNCVkeHUh?=
SW1710 MlfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TNUWlEPTB;MD6wO|UyKG6P NH31PItUSU6JRWK=
DEL NYP1bFBJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTBwMEi4O{BvVQ>? M3P6VnNCVkeHUh?=
AGS M4ToSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHITWM2OD1yLkC5NFIhdk1? M{mzXHNCVkeHUh?=
NCI-H2122 NGfrZ5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfVN2ZKSzVyPUCuNFk1PiCwTR?= NHvpN41USU6JRWK=
HSC-4 NEjXeXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zpTGlEPTB;MD6xNFIhdk1? M3jR[3NCVkeHUh?=
AM-38 NW\rd2h3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XRUmlEPTB;MD6xNlEhdk1? NXrvbGhQW0GQR1XS
769-P M4XkSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml[0TWM2OD1yLkGyN{BvVQ>? NILEXndUSU6JRWK=
RT-112 NWjNPXZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFP6fYxKSzVyPUCuNVI4KG6P NHfYTHNUSU6JRWK=
MCF7 NITMPYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\VenpKSzVyPUCuNVM3KG6P MWjTRW5ITVJ?
IGROV-1 NEPmS5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nQW2lEPTB;MD6xOFUhdk1? NVzI[nBqW0GQR1XS
OCI-AML2 M1zBfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTBwMUS3JI5O M{LGUXNCVkeHUh?=
NCI-H1299 NVyzPVB1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPWOFdOUUN3ME2wMlE2PyCwTR?= Mn36V2FPT0WU
A431 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDrdWhKSzVyPUCuNVg{KG6P NHX2fZVUSU6JRWK=
SW982 NY\ZTYRnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTBwMkGzJI5O M4XST3NCVkeHUh?=
BB30-HNC MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTnbnZKSzVyPUCuNlMyKG6P MWrTRW5ITVJ?
ACN MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXXTWM2OD1yLkK0OEBvVQ>? NHzvZ3ZUSU6JRWK=
647-V NFTJXVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV:1V4NmUUN3ME2wMlI1QCCwTR?= MYfTRW5ITVJ?
SK-PN-DW MlfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPhW3pEUUN3ME2wMlI3PiCwTR?= NGH4dGlUSU6JRWK=
LCLC-97TM1 M2HtOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnifY1KSzVyPUCuNlY4KG6P Mn:5V2FPT0WU
LB1047-RCC MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfIe|hKSzVyPUCuNlY6KG6P MVzTRW5ITVJ?
A2780 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH22OldKSzVyPUCuNlchdk1? M4[3fnNCVkeHUh?=
C-33-A MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TPRWlEPTB;MD6yO|Mhdk1? NYnUb25uW0GQR1XS
NCI-H2228 M3\6Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrvfGpxUUN3ME2wMlMyPCCwTR?= MYLTRW5ITVJ?
TE-5 M1q4Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvnb2lKSzVyPUCuN|E3KG6P M1TwdnNCVkeHUh?=
HC-1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmH4TWM2OD1yLkOyO{BvVQ>? MlfLV2FPT0WU
SK-MES-1 NEnUbohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\LWWpKSzVyPUCuN|I5KG6P NHjkfHlUSU6JRWK=
NCI-H1355 NFLhUIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGqxT2dKSzVyPUCuN|gyKG6P NXXyNWtzW0GQR1XS
YKG-1 M3LSUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjYVoV3UUN3ME2wMlQyQSCwTR?= MWrTRW5ITVJ?
RS4-11 M3nCRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFiycZhKSzVyPUCuOFM{KG6P NF\obZJUSU6JRWK=
Daoy Mn;1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjLU3E3UUN3ME2wMlQ2PiCwTR?= MnfiV2FPT0WU
A3-KAW NGTtNZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTBwNUWxJI5O NYiwcGVlW0GQR1XS
SK-MEL-30 NWXmOXdvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjTdYxKSzVyPUCuOVU1KG6P M1TQOHNCVkeHUh?=
U031 M4nsfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTBwNU[1JI5O MUPTRW5ITVJ?
SK-LMS-1 NWfQO2lFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3PTWM2OD1yLkW3PEBvVQ>? NFnnN5JUSU6JRWK=
ES6 M2jrdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF[4XJFKSzVyPUCuOVg3KG6P NWjTcoFjW0GQR1XS
EoL-1-cell MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTKfYg2UUN3ME2wMlYyPiCwTR?= MmjCV2FPT0WU
NCI-H2009 NE\6dJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLudodKSzVyPUCuOlE6KG6P M17pVXNCVkeHUh?=
A4-Fuk MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\Xd3hsUUN3ME2wMlYzPiCwTR?= M4e5bnNCVkeHUh?=
KYSE-270 NWDKWFR1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;rWWpKSzVyPUCuOlM1KG6P NEXyfplUSU6JRWK=
SK-LU-1 Mmn3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjz[2xKSzVyPUCuOlU2KG6P Mmn4V2FPT0WU
SW872 NY[0SZJYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;uUGlEPTB;MD63OlUhdk1? NVrhSmRyW0GQR1XS
ES8 M1\rV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjKcoU6UUN3ME2wMlc5KG6P MWPTRW5ITVJ?
G-402 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTmTWM2OD1yLke4OEBvVQ>? NFnaOJdUSU6JRWK=
ATN-1 M1n5[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTBwOEC3JI5O NH;DfolUSU6JRWK=
DoTc2-4510 NVr6dYFHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTBwOUCxJI5O NUjHWoNZW0GQR1XS
MES-SA NGLvUYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFi4TWNKSzVyPUCuPVA2KG6P MYHTRW5ITVJ?
SF268 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTBwOUK3JI5O NYLEUVZwW0GQR1XS
SF539 M{L2Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37wWWlEPTB;MT6wNkBvVQ>? MVfTRW5ITVJ?
NB69 NUj1SGV4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTFwMEWgcm0> NEDZSppUSU6JRWK=
8505C NFLBUHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXy3elk4UUN3ME2xMlA3KG6P MX;TRW5ITVJ?
CAL-12T NVfrOVRkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{n1XmlEPTB;MT6wPEBvVQ>? MXTTRW5ITVJ?
BHY NV7lVlhYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrZTWM2OD1zLkG0JI5O MXTTRW5ITVJ?
LB647-SCLC NYDTVGsyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnUT2NKSzVyPUGuNVghdk1? NHzxNWdUSU6JRWK=
CAL-62 NX3Mc2Z5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTFwMkKgcm0> M2P2N3NCVkeHUh?=
MEG-01 M1HGdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33lVWlEPTB;MT6yO{BvVQ>? MmPoV2FPT0WU
MG-63 MkTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTFwM{Ogcm0> MmjTV2FPT0WU
SW620 MnfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPpfYlzUUN3ME2xMlM2KG6P M3jCeHNCVkeHUh?=
A388 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PVUGlEPTB;MT6zOkBvVQ>? MWTTRW5ITVJ?
BCPAP NYn4W2tXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrxSndKSzVyPUGuOFUhdk1? M{C2ZnNCVkeHUh?=
P30-OHK NV7yR3BCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTFwNE[gcm0> MlO3V2FPT0WU
Ca9-22 NHnvfIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fRRmlEPTB;MT61OEBvVQ>? MVjTRW5ITVJ?
VMRC-RCZ NXW4NFd3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXHUow2UUN3ME2xMlU1KG6P M{PmTnNCVkeHUh?=
LOXIMVI M{D1OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnH0TWM2OD1zLk[gcm0> NGTwPZZUSU6JRWK=
L-540 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTFwNjDuUS=> NWPl[lR2W0GQR1XS
NTERA-S-cl-D1 M2jEWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTFwNkSgcm0> MmroV2FPT0WU
MFH-ino NE\MXY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTFwNk[gcm0> M1PHcnNCVkeHUh?=
Calu-6 M3;ScGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TIb2lEPTB;MT63N{BvVQ>? NFThfYdUSU6JRWK=
HEL NI[3XpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTFwN{mgcm0> M1L6d3NCVkeHUh?=
CAL-33 NEXOcGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TtemlEPTB;MT64PUBvVQ>? NWfJZ5R7W0GQR1XS
HSC-3 NYXnco5ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\BTWM2OD1zLkmxJI5O M{G3VnNCVkeHUh?=
KU812 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjrZWxKSzVyPUGuPVEhdk1? M123O3NCVkeHUh?=
EB2 NEDzbJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTJwMEGgcm0> MV3TRW5ITVJ?
SR MlrZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTJwMUKgcm0> NV\aeGYzW0GQR1XS
NCI-H2087 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zlW2lEPTB;Mj6xOEBvVQ>? NUfOPZRkW0GQR1XS
H4 MlXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rKcWlEPTB;Mj6xPEBvVQ>? M1TqWHNCVkeHUh?=
EW-1 NIXGTGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILLZ2VKSzVyPUKuNlIhdk1? NWHhOJJSW0GQR1XS
MC-IXC M{fyOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rlO2lEPTB;Mj6yOkBvVQ>? MWDTRW5ITVJ?
NCI-H727 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTnTWM2OD1{LkWxJI5O NF\qNYFUSU6JRWK=
MRK-nu-1 NVvvcJZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jpfmlEPTB;Mj61O{BvVQ>? NYPPWXJqW0GQR1XS
COLO-668 NYPPRmRvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPuW2pKSzVyPUKuOlYhdk1? NVnFV|FLW0GQR1XS
CGTH-W-1 MlnKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTJwN{Kgcm0> NHX1VpRUSU6JRWK=
CHP-212 MlrJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDnTWM2OD1{Lke1JI5O NYj5OGRlW0GQR1XS
GI-1 M4DUfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LkeGlEPTB;Mj63OkBvVQ>? NGHo[GZUSU6JRWK=
HCC1806 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTJwOUGgcm0> M33oPXNCVkeHUh?=
HLE MmLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGS0XWpKSzVyPUOgcm0> M{LKd3NCVkeHUh?=
HSC-2 NF6yeFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPKOoZKSzVyPUOuNFMhdk1? NUm0U4hwW0GQR1XS
DMS-273 NGrYd3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTNwMEegcm0> M1iwenNCVkeHUh?=
DU-4475 Mm\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTNwMUSgcm0> MnfQV2FPT0WU
LXF-289 NGnF[ZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlX4TWM2OD1|LkOxJI5O M2f2UXNCVkeHUh?=
PANC-03-27 NEj6ZpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXuxNVgxUUN3ME2zMlUyKG6P M{ToXHNCVkeHUh?=
GAMG NYjlT3ZKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlm2TWM2OD1|Lke0JI5O MoHkV2FPT0WU
NCI-H522 M{DzTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn34TWM2OD12LkO0JI5O MlXwV2FPT0WU
SW626 MmTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTRwNE[gcm0> NYnzfo1DW0GQR1XS
HT-144 M{fyXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2C1VGlEPTB;ND65NkBvVQ>? Mlm0V2FPT0WU
MEL-HO M3TYUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTVwMU[gcm0> NYm5RW5nW0GQR1XS
BE-13 NXzm[GN6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTVwMkGgcm0> NXjKb5FSW0GQR1XS
VA-ES-BJ M4\BdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvudYhKSzVyPUWuNlYhdk1? M3m5fnNCVkeHUh?=
NCI-H441 NHf3VGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljyTWM2OD13Lk[gcm0> MmrBV2FPT0WU
KP-4 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zPcGlEPTB;NT62NUBvVQ>? MlHaV2FPT0WU
LoVo NELWcWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XjeGlEPTB;NT63NUBvVQ>? MmW3V2FPT0WU
HT-1080 NFr5TXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTVwOEOgcm0> MUjTRW5ITVJ?
GB-1 M1vxOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjqTWM2OD13Lki0JI5O MXvTRW5ITVJ?
IA-LM Mo[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DMT2lEPTB;NT65NUBvVQ>? M3TOZXNCVkeHUh?=
8-MG-BA Mnj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLabVFQUUN3ME21Mlk{KG6P MnK1V2FPT0WU
SK-HEP-1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrae|BKSzVyPU[uNVQhdk1? NX[3RnBjW0GQR1XS
697 MoTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFO2T4dKSzVyPU[uNlUhdk1? M1HyPHNCVkeHUh?=
KYSE-450 NX3Pcpo{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\sTWM2OD14LkOyJI5O MknjV2FPT0WU
HCC2998 MmmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3sN4JKSzVyPU[uN|Qhdk1? M2jiR3NCVkeHUh?=
HD-MY-Z MkDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3L4fGlEPTB;Nj62PEBvVQ>? M3HF[nNCVkeHUh?=
OS-RC-2 NIHVZpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml[2TWM2OD14Lk[4JI5O M4T0dHNCVkeHUh?=
SF126 M3PZUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHRdWhKSzVyPUeuNFUhdk1? NHvEd|ZUSU6JRWK=
Ca-Ski NGO2empIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml71TWM2OD15LkC5JI5O NY\JbZIyW0GQR1XS
NCI-H358 NVHlO3NKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTdwMU[gcm0> Mo[wV2FPT0WU
J82 NYfYcVlST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;O[Wd7UUN3ME23MlQyKG6P Mn3PV2FPT0WU
NCI-H2342 MnWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzHT4F5UUN3ME23MlY{KG6P MojPV2FPT0WU
OVCAR-8 NU\tc2dtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4W2VWlEPTB;Nz65JI5O MmfjV2FPT0WU
TE-8 M4fN[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRThibl2= NGnMS4VUSU6JRWK=
ETK-1 MkfDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3S4WWlEPTB;OD6wPEBvVQ>? MXnTRW5ITVJ?
HAL-01 MkP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWWxVIFPUUN3ME24MlIhdk1? NHrmZ3hUSU6JRWK=
KYSE-150 NGPscGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2n0d2lEPTB;OD60O{BvVQ>? MmPHV2FPT0WU
NCI-H810 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXq3PGlEUUN3ME24MlU3KG6P MYLTRW5ITVJ?
ONS-76 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRThwNkigcm0> Mn:1V2FPT0WU
NMC-G1 M4i0Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfae25KSzVyPUiuO|Yhdk1? NYPHPWNvW0GQR1XS
C3A NHvWbFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkT1TWM2OD16Lki0JI5O M3XtOnNCVkeHUh?=
PA-1 NVrwNmJYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2j5[mlEPTB;OD65PUBvVQ>? MXXTRW5ITVJ?
SH-4 MlrnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDhW5VKSzVyPUmuNFIhdk1? MmP1V2FPT0WU
EFO-27 NWPWcZVGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWH5ZXhIUUN3ME25MlA2KG6P NGjkWVlUSU6JRWK=
CAPAN-1 M2DFPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTlwMkOgcm0> MVXTRW5ITVJ?
DU-145 NYfjV4tFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmOyTWM2OD17LkK5JI5O M3;oUXNCVkeHUh?=
A101D MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTlwM{egcm0> MkfUV2FPT0WU
ST486 NVLMe5dlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETtbW1KSzVyPUmuOFEhdk1? M3nnSHNCVkeHUh?=
NCI-H1437 MmfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fWRmlEPTB;OT60NkBvVQ>? MXjTRW5ITVJ?
HGC-27 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3wZWZKSzVyPUmuOkBvVQ>? Mmr6V2FPT0WU
8305C NFvSW5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofHTWM2OD17Lk[0JI5O MkLPV2FPT0WU
OCUB-M M2HXPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWCxeZYzUUN3ME2xNE4xOyCwTR?= NWWycGpyW0GQR1XS
COLO-679 Mn6yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTFyLkC3JI5O MkLRV2FPT0WU
Detroit562 NFvlb2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjTc|JKSzVyPUGwMlQzKG6P NW\ENmI6W0GQR1XS
A204 M2P0fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTFzLkG2JI5O NFPqfI5USU6JRWK=
NCI-H1734 NH3iO4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHYb5A6UUN3ME2xNU4zQSCwTR?= Mor0V2FPT0WU
MC-CAR NXvBU2xrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLGTWM2OD1zMT61PEBvVQ>? NIfBTI1USU6JRWK=
NCI-H2170 NH7Rc3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELMSI1KSzVyPUGxMlk4KG6P NIfmbYxUSU6JRWK=
NCI-SNU-5 M{PRNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTF{LkGzJI5O M{HMPXNCVkeHUh?=
HCE-T MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTF{LkSyJI5O NWDWV5ExW0GQR1XS
KYSE-180 NV;vdWczT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTF{LkixJI5O MYHTRW5ITVJ?
C8166 NYnOS|JoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDyZYZKSzVyPUGzMlA5KG6P NHr1[WFUSU6JRWK=
NCI-H460 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PWdWlEPTB;MUOuOVQhdk1? MX7TRW5ITVJ?
SNU-449 M1HRWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkGyTWM2OD1zMz63O{BvVQ>? M37lTHNCVkeHUh?=
MDA-MB-468 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHQUFhKSzVyPUG0MlEzKG6P NHPK[41USU6JRWK=
COR-L23 M3\qdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vISGlEPTB;MUSuNVMhdk1? M3XkcnNCVkeHUh?=
CTV-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTF2LkG0JI5O NIrQUW5USU6JRWK=
BL-41 NV;6XZlNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInpOYpKSzVyPUG0MlM4KG6P MmLYV2FPT0WU
IGR-1 MkjjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfJTWM2OD1zND60NkBvVQ>? NXfGXINRW0GQR1XS
TK10 MlrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTF2LkS5JI5O NXLWUpR5W0GQR1XS
REH NVi3RWNMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTF2LkWxJI5O NGfJOWtUSU6JRWK=
LU-139 NVjVU3JKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\tbWRKSzVyPUG0MlU6KG6P NIjVVYNUSU6JRWK=
KP-N-YS MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPQfllRUUN3ME2xOE46PyCwTR?= M{nwdnNCVkeHUh?=
PANC-10-05 NHuySIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfGTWM2OD1zNT6zPEBvVQ>? MWjTRW5ITVJ?
HL-60 Mlq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1uyXGlEPTB;MUWuOlkhdk1? NX3NUGR{W0GQR1XS
T84 NGDvOo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHoeFVTUUN3ME2xOU46PiCwTR?= M325SnNCVkeHUh?=
RPMI-8226 M2TlZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXKzTFdwUUN3ME2xOk4xOiCwTR?= M4foZ3NCVkeHUh?=
UM-UC-3 MnWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLwTHlKSzVyPUG2MlE3KG6P MXHTRW5ITVJ?
TE-10 MkHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkCwTWM2OD1zNj6yNUBvVQ>? M17wZnNCVkeHUh?=
CAL-148 NFz5OoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTF5LkKzJI5O NHy2NJFUSU6JRWK=
BV-173 NET4dVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfnPVh2UUN3ME2xO{4zPyCwTR?= MVnTRW5ITVJ?
Calu-3 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;jSGNKSzVyPUG3MlI6KG6P MX\TRW5ITVJ?
RPMI-2650 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTF5LkW5JI5O NYnxZZJbW0GQR1XS
MKN45 NUPqd2c3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF[5WGtKSzVyPUG3Mlc{KG6P MUjTRW5ITVJ?
NUGC-3 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4r2e2lEPTB;MUiuN|Qhdk1? NFOxUW5USU6JRWK=
NCI-H520 Mmr1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTF6Lke3JI5O M2\BdHNCVkeHUh?=
CCRF-CEM M1rBXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTF6Lki1JI5O NGLiXnRUSU6JRWK=
NCI-H2405 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mli0TWM2OD1zOT6xJI5O MnjOV2FPT0WU
ES7 NFrL[pdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml:3TWM2OD1zOT63OkBvVQ>? NEnaXI5USU6JRWK=
BPH-1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7vcHVLUUN3ME2yNE4zQCCwTR?= NH;4U4FUSU6JRWK=
SAS NFXKSplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTJyLkWgcm0> MUjTRW5ITVJ?
HuCCT1 M3fRdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M322TGlEPTB;MkCuOVghdk1? M2XuTXNCVkeHUh?=
LOUCY NUHOUYFXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3TN5FEUUN3ME2yNE43PiCwTR?= NVH0R29rW0GQR1XS
NCI-H292 MlrnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTJyLke5JI5O MkCyV2FPT0WU
G-361 M33HV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkO2TWM2OD1{MT6wO{BvVQ>? MorCV2FPT0WU
M059J MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4GwWGlEPTB;MkGuNFghdk1? M3rkXHNCVkeHUh?=
NCI-H1651 Mny3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjlW5NyUUN3ME2yNU4yOSCwTR?= Moe1V2FPT0WU
KALS-1 MnzRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\QTWM2OD1{MT6zPUBvVQ>? MVrTRW5ITVJ?
DJM-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3ySVFCUUN3ME2yNU42QSCwTR?= NYS3[mM5W0GQR1XS
AU565 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTJzLkizJI5O M2LRSXNCVkeHUh?=
HCC38 MmjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTJzLkm1JI5O M1HGTnNCVkeHUh?=
U251 M1PnbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjLTWM2OD1{Mj6yO{BvVQ>? MXHTRW5ITVJ?
ABC-1 NFPnSmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3WV2pKSzVyPUKyMlY2KG6P NYnVU3lpW0GQR1XS
SK-NEP-1 M2P5XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkH4TWM2OD1{Mj65N{BvVQ>? Mn;QV2FPT0WU
CESS MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXUXG5KSzVyPUKzMlE6KG6P NFfDOWRUSU6JRWK=
MIA-PaCa-2 M4O1fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzYTWM2OD1{Mz6zOkBvVQ>? NF\CW5JUSU6JRWK=
SUP-T1 NFvNUINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnUdm01UUN3ME2yN{41PyCwTR?= MWTTRW5ITVJ?
L-428 NGHwdoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jOTWlEPTB;MkOuOlIhdk1? NG[0SFZUSU6JRWK=
SW954 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHycm1KSzVyPUKzMlY5KG6P MUnTRW5ITVJ?
HO-1-N-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTJ|Lke3JI5O NHrmW2NUSU6JRWK=
CHP-126 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jDNmlEPTB;MkSuNVQhdk1? M4rVVnNCVkeHUh?=
HMV-II MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2n4SWlEPTB;MkSuN|Qhdk1? NFz0XXNUSU6JRWK=
NB10 M2nlTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDGTWM2OD1{ND6zO{BvVQ>? NF\pRWFUSU6JRWK=
A172 M3zxW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHr3U|VKSzVyPUK0MlcyKG6P NVfSeVFWW0GQR1XS
MONO-MAC-6 NE\sV4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7BfZNKSzVyPUK0Mlg1KG6P NIfwT2RUSU6JRWK=
NCI-H1650 M{fpN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTJ3LkSgcm0> MVnTRW5ITVJ?
NH-12 M2j1emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDV[nhKSzVyPUK1MlUhdk1? MWHTRW5ITVJ?
ML-2 NWnYT3R7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;4blBKSzVyPUK1Mlc1KG6P M{HY[3NCVkeHUh?=
MZ2-MEL NELWR4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHmbWhKSzVyPUK2MlIzKG6P NEDUWGxUSU6JRWK=
COLO-684 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrQTWM2OD1{Nj60NUBvVQ>? M1WyfHNCVkeHUh?=
HuP-T4 NVz0U2JtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkD4TWM2OD1{Nz6zJI5O MlriV2FPT0WU
SW837 NUjVXoFIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1q3[mlEPTB;MkeuOlIhdk1? NFSyZmdUSU6JRWK=
MDA-MB-231 NH31eItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nWSmlEPTB;MkeuO|ghdk1? NFjxW4RUSU6JRWK=
KYSE-140 NX\0VIhDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTJ5LkmxJI5O NHjKNYJUSU6JRWK=
NOMO-1 MlzGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnDTm1vUUN3ME2yPE43QCCwTR?= MYHTRW5ITVJ?
GP5d NUDtZZZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnP3TWM2OD1{OD63NkBvVQ>? NHrSdIFUSU6JRWK=
COR-L105 NHnZfWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PLS2lEPTB;MkmuOFIhdk1? NXTPdZdHW0GQR1XS
LS-411N MnHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmq2TWM2OD1{OT64PEBvVQ>? NFW3WmtUSU6JRWK=
NY NXTuW2twT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn:4TWM2OD1|MD6xPEBvVQ>? NXy1PGN5W0GQR1XS
NCI-H2030 M17HcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTNyLkS1JI5O MWDTRW5ITVJ?
CCF-STTG1 M37OW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY[4do5KUUN3ME2zNU41OiCwTR?= NX3kPYxOW0GQR1XS
NCI-H1703 NWjZ[|FDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTNzLke4JI5O NFPFSVVUSU6JRWK=
TUR NX71SW5iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDmTWM2OD1|Mj6wN{BvVQ>? MmLnV2FPT0WU
NOS-1 NXzVUlZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3m0e2lEPTB;M{KuOFQhdk1? M2HaU3NCVkeHUh?=
A2058 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLkTWM2OD1|Mj64N{BvVQ>? MmiwV2FPT0WU
LCLC-103H MomxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHYPZJpUUN3ME2zN{4zPSCwTR?= MojMV2FPT0WU
NCI-H510A M1rpemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrqTWM2OD1|Mz6yO{BvVQ>? MWjTRW5ITVJ?
BC-1 NUXReodiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3uVFVKSzVyPUOzMlc4KG6P MXzTRW5ITVJ?
SK-CO-1 M2LDdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TKWWlEPTB;M{SuNFEhdk1? MnnMV2FPT0WU
A673 MlzZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTN2LkG3JI5O NX3seVRIW0GQR1XS
VM-CUB-1 MoLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnMW2pKSzVyPUO0MlY6KG6P MoHWV2FPT0WU
HH NWPQXFhIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnjcW9KSzVyPUO1MlA3KG6P NVnIcFFKW0GQR1XS
CAL-27 M{fvOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkCyTWM2OD1|NT6xOkBvVQ>? NGTYRpJUSU6JRWK=
NEC8 M1\sOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFz6VWJKSzVyPUO1MlM4KG6P MYfTRW5ITVJ?
BxPC-3 NWXKcplLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;HTWM2OD1|Nj65NUBvVQ>? NFjjbXdUSU6JRWK=
SNB75 NH;RSJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnyzTWM2OD1|Nz6yOEBvVQ>? MVLTRW5ITVJ?
NB13 MonGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTN6LkKzJI5O MXXTRW5ITVJ?
SK-OV-3 NIWz[JBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvZTWM2OD1|OD63OEBvVQ>? Mmi5V2FPT0WU
ME-180 MmW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnlZpNKSzVyPUO4Mlghdk1? MWrTRW5ITVJ?
JiyoyeP-2003 MlHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTLTFNKSzVyPUO5MlM5KG6P MX;TRW5ITVJ?
LU-134-A MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1joe2lEPTB;NECuNFIhdk1? NIDFR|NUSU6JRWK=
LS-123 NI\LeJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTRyLkK4JI5O NWq5S|R2W0GQR1XS
COLO-800 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIO5S5VKSzVyPUSwMlU3KG6P NHXse5ZUSU6JRWK=
LB831-BLC M4e5Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjGbHpuUUN3ME20NU45PSCwTR?= M4X0bXNCVkeHUh?=
NCI-H747 M3zMT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jSfGlEPTB;NEKuNlghdk1? M1u2RnNCVkeHUh?=
MZ7-mel Mni1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkSyTWM2OD12Mj62OkBvVQ>? M1HJTnNCVkeHUh?=
GT3TKB NYfnN3h1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjNTWM2OD12Mj63NkBvVQ>? M1\zdHNCVkeHUh?=
MOLT-16 M{nVNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\pXY1mUUN3ME20N{4xPSCwTR?= M{XMdnNCVkeHUh?=
23132-87 NX\nT2xtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWf6RnlTUUN3ME20N{4xPSCwTR?= MXrTRW5ITVJ?
PF-382 NXnRWnVET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\uclJnUUN3ME20OE4zOiCwTR?= M3PuRXNCVkeHUh?=
ES3 M4rPNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDZNnVQUUN3ME20OE43KG6P MoCwV2FPT0WU
SW756 MmnLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\PeGQ5UUN3ME20OU4yPCCwTR?= MmnGV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo Gemcitabine combined with C225 results in growth inhibition, tumor regression, and abrogation of metastasis in L3.6pl tumors established in the pancreas of nude mice. Gemcitabine treatment alone reduces median tumor volume from 538 to 152 mm3. Gemcitabine reduces the production of vascular endothelial growth factor and interleukin 8 in gemcitabine-treated tumors. [2] Gemcitabine is able to dramatically and specifically reduces the number of myeloid suppressor cells found in the spleens of animals bearing large tumors with no significant reductions in CD4(+) T cells, CD8(+) T cells, NK cells, macrophages, or B cells. [4] Gemcitabine combined with curcumin shows significant reductions in volume (P = 0.008 versus control; P = 0.036 versus gemcitabine alone), Ki-67 proliferation index (P = 0.030 versus control), NF-kappaB activation, and expression of NF-kappaB-regulated gene products (cyclin D1, c-myc, Bcl-2, Bcl-xL, cellular inhibitor of apoptosis protein-1, cyclooxygenase-2, matrix metalloproteinase, and vascular endothelial growth factor) compared with tumors from control mice treated with olive oil only. Gemcitabine combined with Curcumin is also highly effective in suppressing angiogenesis as indicated by a decrease in CD31(+) microvessel density. [5]

Protocol

Solubility (25°C)

In vitro DMSO 52 mg/mL (197.56 mM)
Water 52 mg/mL warmed (197.56 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
water (warmed)
For best results, use promptly after mixing.
52mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 263.2
Formula

C9H11F2N3O4

CAS No. 95058-81-4
Storage powder
in solvent
Synonyms LY-188011, NSC 613327

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02181634 Active, not recruiting Cholangiocarcinoma PrECOG, LLC.|Celgene Corporation December 9, 2014 Phase 2
NCT01535924 Recruiting Adult Lymphocyte Depletion Hodgkin Lymphoma|Adult Lymphocyte Predominant Hodgkin Lymphoma|Adult Mixed Cellularity Hodgkin Lymphoma|Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma|Adult Nodular Sclerosis Hodgkin Lymphoma|Recurrent Adult Hodgkin Lymphoma Kristie Blum|Ohio State University Comprehensive Cancer Center February 9, 2012 Phase 1|Phase 2
NCT01285037 Recruiting Cancer Eli Lilly and Company September 9, 2009 Phase 1
NCT01828736 Completed Recurrent Bladder Cancer|Stage IV Bladder Cancer|Transitional Cell Carcinoma of the Bladder Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie|Roche Pharma AG February 9, 2004 Phase 2
NCT01352962 Active, not recruiting Urethral Neoplasms|Neoplasms, Urethral|Ureter Cancer|Cancer of the Urethra|Urethral Cancer National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 5, 2011 Phase 1
NCT03027284 Recruiting Advanced Cancer|Metastatic Cancer|Biliary Tract Carcinoma|Cholangiocarcinoma|Gall Bladder Carcinoma|Solid Tumor|Non-Hodgkins Lymphoma Eli Lilly and Company February 3, 2017 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What is the difference between gemcitabine(S1714 ) and Gemcitabine HCl (S1149)?

  • Answer:

    Gemcitabine HCl is the HCl salt form of Gemcitabine. They have the same biological activities. The free base(S1714) dissolves better in DMSO, and the hydrochloride (S1149) dissolves better in water.

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

Tags: buy Gemcitabine | Gemcitabine ic50 | Gemcitabine price | Gemcitabine cost | Gemcitabine solubility dmso | Gemcitabine purchase | Gemcitabine manufacturer | Gemcitabine research buy | Gemcitabine order | Gemcitabine mouse | Gemcitabine chemical structure | Gemcitabine mw | Gemcitabine molecular weight | Gemcitabine datasheet | Gemcitabine supplier | Gemcitabine in vitro | Gemcitabine cell line | Gemcitabine concentration | Gemcitabine nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID